MarketCatalyst
← Back to Resources
Earnings

Nektar Therapeutics Q3 2026 EPS Tops Estimates at -$1.63, but Revenue Misses at $9.4M

Revenue of $9.4M vs. $10.3M expected and adjusted EPS of -$1.63 vs. -$2.07; revenue down 20% from a year earlier.

Published Nov 12, 2026 · 4:16 PM ET · 2 min read

Nektar Therapeutics (NKTR) posted mixed third-quarter 2026 results, with adjusted EPS above the estimate and revenue below it. Revenue was $9.4 million, down 20% from a year earlier, below the $10.3 million estimate, and adjusted EPS was -$1.63, up 12% from a year earlier, above the -$2.07 estimate.

Shares fell 0.7% in after-hours trading as of 4:15 p.m. ET, to $37.00 from a $37.25 close.

-$1.63
Adjusted EPS, up 12% YoY vs. -$2.07 estimate
$9.4M
Revenue, down 20% YoY vs. $10.3M estimate
-0.7%
Shares after hours as of 4:15 p.m. ET

Q3 2026 scorecard

ParametersExpectedActualBeat/Miss
Adjusted EPS-$2.07-$1.63Beat by 21%
Revenue$10.3M$9.4MMiss by 8.6%
ChangeYoYQoQ
Adjusted EPS▲ 12%▼ 33%
Revenue▼ 20%▼ 7.4%

By our calculation, revenue was $888 thousand below the estimate and adjusted EPS was $0.44 above it. The QoQ column compares with the previous quarter's revenue of $10.1 million and adjusted EPS of -$1.23. The YoY column compares with $11.8 million and -$1.85 in the same quarter a year earlier.

Track record

  • EPS record. Adjusted EPS beat the estimate in 6 of the last 8 reports, including this one.
  • Revenue record. Revenue beat the estimate in 4 of the last 8 reports.
  • Revenue trend. Revenue over the last 5 reports, oldest first: $11.8 million, $21.8 million, $10.9 million, $10.1 million and $9.4 million.

What to watch

  • Next-quarter estimates. Consensus calls for EPS of -$2.76 and revenue of $10.5 million next quarter, based on 12 analysts.
  • Revenue growth. Whether revenue stabilizes after this quarter's 20% decline from a year earlier to $9.4 million.
  • Estimate record. Whether Nektar Therapeutics extends a record of beating EPS estimates in 6 of its last 8 reports.
  • Related coverage. See our reports on Jefferson Capital, Flowers Foods, Cisco Systems and Cerebras Systems.

Sources: Results are from Nektar Therapeutics's Nov. 12, 2026 quarterly report. Estimates are consensus figures. The prior-quarter and year-ago comparison figures are from Nektar Therapeutics's earlier quarterly reports. Items labeled by our calculation are our own arithmetic. This article is informational only and is not investment advice.

Readers also read

MarketCatalyst is not a registered investment advisor and does not manage client assets. Content on this platform is provided for informational and educational purposes only. It is not investment advice, and MarketCatalyst is not a stock-picking or trade-alert service. Trading stocks and options involves risk, including the possible loss of principal. Consider your own goals, time horizon, and risk tolerance, and consult a qualified financial advisor before making any investment decision.